SEC filings and other documents

GRI-0621 Phase 2a in IPF showed zero cough, improved safety, and cash runway into Q2 2027.

Reverse stock split and adjournment proposals approved; results to be filed on Form 8-K.

Net loss rose to $9.3M YTD; cash runway extends into Q1 2026, but funding uncertainty remains.

Phase 2A data for GRI-0621 in IPF expected soon, with pipeline progress in lupus and fibrosis.

Cash runway extends into Q4 2025, but ongoing losses require new funding for continued operations.

Innovative NKT modulators show promise for IPF and SLE, targeting major unmet needs.

Phase 2A IPF trial of NKT cell inhibitor shows early safety and antifibrotic signals; top-line data due Q3.

Phase 2a IPF trial of NKT cell inhibitor shows early safety and antifibrotic signal, with key data due soon.

Positive interim IPF trial data and $5M financing extend GRI Bio's cash runway through Q3 2025.

GRI Bio advances IPF pipeline with strong clinical progress and cash runway into Q2 2025.

NKT cell modulators target early inflammation in IPF and SLE, showing strong preclinical promise.

GRI Bio advances GRI-0621 for IPF, with key clinical data expected in 2025 and strong cash position.

GRI Bio advances GRI-0621 for IPF, maintains cash runway into Q1 2025, and plans further fundraising.